查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
勃起功能障礙 (ED) 藥物市場：成長、未來展望與競爭分析（2025-2033 年）
市場調查報告書
商品編碼
1675076

勃起功能障礙 (ED) 藥物市場：成長、未來展望與競爭分析（2025-2033 年）

Erectile Dysfunction (ED) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
出版日期: | 出版商: Acute Market Reports | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

勃起功能障礙（ED）藥物是用於治療勃起功能障礙的藥物－勃起功能障礙的特徵是無法達到或維持足以進行令人滿意的性活動的勃起。治療勃起功能障礙的藥物通常會透過增加流向陰莖的血流量來發揮作用，主要是透過抑制調節血管擴張的某些酵素。最常見的治療 ED 藥物包括 5 型磷酸二酯酶抑制劑 (PDE5 抑制劑)，但根據患者的健康狀況和功能障礙的根本原因，也會使用其他類別的藥物。勃起功能障礙藥物市場預計將以 3.2% 的複合年成長率 (CAGR) 成長。推動這種成長的因素是糖尿病、高血壓和荷爾蒙失調等疾病的發病率不斷上升，這些疾病通常與 ED 的發展有關。

世界人口老化

勃起功能障礙（ED）藥物市場的主要驅動力是世界人口老化。隨著已開發國家和新興國家人口老化，糖尿病、高血壓、心血管疾病等慢性病的發生率將會增加，而這些慢性病是導致ED的重要危險因子。年齡是影響 ED 盛行率的重要人口因素，40 多歲的男性中約有 5% 患有 ED，65 歲以上的男性中約有 15-25% 患有 ED。由於老齡化人口尋求解決方案以維持令人滿意的生活品質，這種人口趨勢正在推動對 ED 藥物的需求。老年人的預期壽命不斷增加以及他們對積極生活方式的渴望進一步推動了這種需求，越來越多的人希望解決影響他們健康和生活品質的健康問題。

遠端醫療及網路藥局

遠端醫療和網路藥局的興起為 ED 藥物市場帶來了巨大的機會。遠端醫療的進步使患者能夠獲得更個人化和便捷的諮詢，這對於患有勃起功能障礙（ED）等帶有社會恥辱的疾病尤其重要。線上平台可以為患者提供一條謹慎的治療途徑，並增強他們治療和控制疾病的動機。此外，網路藥局改善了人們獲得治療勃起功能障礙藥物的管道，擴大了市場覆蓋範圍，尤其是在農村和服務不足的地區。此類平台通常提供更好的定價模式和可近性，使治療選擇更實惠、更快捷，從而有可能提高市場滲透率和患者對處方治療的依從性。

專利到期

治療勃起功能障礙的藥物市場的主要限制因素是主要暢銷藥物的專利到期。當專利到期後，學名藥就會進入市場，大大降低品牌藥製造商的價格和收益。例如，Sildenafil（威而鋼）非專利藥的推出大大降低了患者的治療費用，但同時也減少了品牌藥製造商輝瑞的市場佔有率和收益。學名藥雖然提高了藥品的可用性和可負擔性，但同時也降低了品牌藥市場現有參與者的利潤率，加劇了競爭，並抑制了新治療方法的創新。

監管和安全問題

勃起功能障礙藥物市場面臨的主要挑戰之一是應對嚴格的法規環境並解決與勃起功能障礙藥物相關的安全問題。治療 ED 的藥物可能會產生嚴重的副作用，並且會與其他藥物相互作用，而硝酸鹽（尤其是用於治療心臟病的硝酸鹽）可能會導致血壓危險下降。在開發新配方的同時確保患者安全需要進行大量的臨床試驗和嚴格的安全測試，這既昂貴又耗時。此外，獲得新藥監管部門的核准需要嚴格的流程，涉及多個階段的測試以證明其功效和安全性。這些障礙對 ED 治療領域的製藥公司構成了挑戰，因為它們減緩了新產品的市場推出速度並涉及大量的財務投資。

藥品市場區隔

勃起功能障礙 (ED) 藥物市場按藥物類型細分為威而鋼、希愛力、Staxyn/艾力達、Stendra/Spedra 和其他。威而鋼（Sildenafil）是 20 世紀 90 年代末首個核准治療勃起功能障礙的口服藥物，由於它是一個成熟的品牌，因此它一直是該類別中銷量最高的藥物。它的高度認可度和豐富的臨床記錄使其成為患者和醫療保健提供者的首選。不過，預計希愛力（他達拉非）未來的複合年成長率最高。這一預計成長是由於西力士的半衰期較長，從而具有更大的自發性，這是與競爭藥物的關鍵區別。此外，西力士的每日一次配方選擇提高了患者的依從性和滿意度，使其不僅作為治療 ED 的方法越來越受歡迎，而且作為治療文明病的方法也越來越受歡迎。

按分銷通路細分市場

根據分銷管道，勃起功能障礙藥物市場細分為醫院藥房、零售藥房和線上藥房。目前，零售藥局憑藉其藥品可及性廣、便利性等優勢，成為此領域收益最高的產業。許多患者更願意從零售藥局購買治療勃起功能障礙的藥物，因為在那裡他們也可以得到藥師的建議和支持。相反，預計在 2025 年至 2033 年期間，網上藥局的複合年成長率最高。這種成長的推動因素是消費者對隱私和便利性的偏好增強，以及線上平台通常提供的具有競爭力的定價模式。遠端醫療服務的興起也推動了網路藥局的發展，越來越多的患者在網路上取處方箋並選擇宅配服務，使得透過這些管道購買勃起功能障礙藥物更具吸引力且更加方便。

勃起功能障礙 (ED) 治療藥物市場的區域趨勢

勃起功能障礙藥物市場呈現出明顯的區域趨勢，其中北美在 2024 年的銷售額方面處於領先地位。這是由於該地區的醫療費用高昂、人們對 ED 治療的認知普遍提高以及大型企業的存在。此外，先進的醫療保健基礎設施以及導致 ED 的糖尿病和高血壓等生活方式相關健康問題的高度流行，支撐了北美強勁的市場需求。然而，預計亞太地區在 2025 年至 2033 年期間的複合年成長率最高。這種成長背後的因素包括醫療保健意識的增強、可支配收入的增加以及這些社會對討論性健康問題的恥辱感的逐漸消除。此外，這些市場中醫療保健體系的不斷擴大和 ED 藥物供應的不斷增加預計將推動顯著成長。

競爭趨勢和關鍵策略

2024 年，勃起功能障礙藥物市場的競爭格局將由主要企業公司、禮來公司、拜耳公司、Vivs 和 Teva Pharmaceutical Industries, Inc. 以及東亞 ST Corporation、SK Chemicals、Meda Pharmaceuticals, Inc.、Crystalia Produtos Kymikos Farmaceutikos、Apricus Biosciences Inc. 和參與者的主要舉措所決定的策略舉措所決定。這些公司正廣泛致力於研究和開發，以推出更有效、更安全的 ED 藥物。輝瑞公司和禮來公司分別擁有標誌性產品威而鋼和希愛力，並透過保持強大的品牌忠誠度和廣泛的全球分銷網路主導了市場。旨在減少副作用和提高患者便利性的創新，如起效更快的製劑和學名藥，是關注領域。 2025 年至 2033 年間，我們預計這些公司將加強實現產品組合多元化，包括探索針對荷爾蒙失衡和血管健康等潛在疾病（而不僅僅是症狀）的 ED治療方法。策略夥伴關係，特別是對於全球擴張和進入新興市場而言，可能極為重要。此外，網路藥局的趨勢可能會鼓勵這些公司加強其數位策略，以覆蓋更廣泛的客戶群。隨著公司適應不斷變化的消費行為和日益激烈的市場競爭，對競爭性定價、病患教育計畫和遠端醫療平台的投資預計將成為關鍵。

目錄

第 1 章 簡介

  • 分析內容
    • 分析目的
    • 目標受眾
    • 主要產品
  • 市場區隔
  • 分析方法
    • 第一階段：二次研究
    • 第二階段：初步調查
    • 第三階段：專家評審
    • 先決條件
    • 採取的方法

第 2 章執行摘要

3. 勃起功能障礙 (ED) 藥物市場：競爭分析

  • 主要供應商的市場定位
  • 供應商所採用的策略
  • 重大產業戰略

4. 勃起功能障礙 (ED) 藥物市場：宏觀分析與市場動態

  • 介紹
  • 2023 年至 2033 年全球勃起功能障礙 (ED) 藥物市場以金額為準
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 主要挑戰
    • 主要機會
  • 促進因素與限制因素影響分析
  • 蹺蹺板分析
  • 波特五力模型
    • 供應商權力
    • 購買者力量
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手之間的競爭
  • PESTEL 分析
    • 政局
    • 經濟情勢
    • 技術狀況
    • 法律狀況
    • 社會狀況

5. 勃起功能障礙 (ED) 藥物市場（依藥物類型分類） (2023-2033)

  • 市場概況
  • 成長與收益分析：2024 年 vs 2033 年
  • 市場區隔
    • 威而鋼
    • 希愛力
    • Staxyn/Levitra
    • 斯特德拉/斯佩德拉
    • 其他

6. 勃起功能障礙 (ED) 藥物市場依分銷管道分類（2023-2033 年）

  • 市場概況
  • 成長與收益分析：2024 年 vs 2033 年
  • 市場區隔
    • 醫院藥房
    • 零售藥局
    • 網路藥局

7. 北美勃起功能障礙 (ED) 藥物市場（2023-2033 年）

  • 市場概況
  • 勃起功能障礙 (ED) 藥物市場（按藥物類型分類） (2023-2033)
  • 勃起功能障礙 (ED) 藥物市場按分銷管道分類（2023-2033 年）
  • 勃起功能障礙 (ED) 藥物市場（按地區） (2023-2033)
    • 北美洲
      • 美國
      • 加拿大
      • 北美其他地區

8.英國和歐盟勃起功能障礙 (ED) 藥物市場（2023-2033 年）

  • 市場概況
  • 勃起功能障礙 (ED) 藥物市場（按藥物類型分類） (2023-2033)
  • 勃起功能障礙 (ED) 藥物市場按分銷管道分類（2023-2033 年）
  • 勃起功能障礙 (ED) 藥物市場（按地區） (2023-2033)
    • 英國和歐盟國家
      • 英國
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 其他歐洲國家地區

9. 亞太地區勃起功能障礙 (ED) 藥物市場（2023-2033 年）

  • 市場概況
  • 勃起功能障礙 (ED) 藥物市場（按藥物類型分類） (2023-2033)
  • 勃起功能障礙 (ED) 藥物市場按分銷管道分類（2023-2033 年）
  • 勃起功能障礙 (ED) 藥物市場（按地區） (2023-2033)
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 其他亞太地區

10. 拉丁美洲勃起功能障礙 (ED) 藥物市場（2023-2033 年）

  • 市場概況
  • 勃起功能障礙 (ED) 藥物市場（按藥物類型分類） (2023-2033)
  • 勃起功能障礙 (ED) 藥物市場按分銷管道分類（2023-2033 年）
  • 勃起功能障礙 (ED) 藥物市場（按地區） (2023-2033)
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲國家

11. 中東和非洲勃起功能障礙 (ED) 藥物市場（2023-2033 年）

  • 市場概況
  • 勃起功能障礙 (ED) 藥物市場（按藥物類型分類） (2023-2033)
  • 勃起功能障礙 (ED) 藥物市場按分銷管道分類（2023-2033 年）
  • 勃起功能障礙 (ED) 藥物市場（按地區） (2023-2033)
    • 中東和非洲
      • GCC
      • 非洲
      • 其他中東和非洲地區

第12章 公司簡介

  • Pfizer Inc.
  • Dong-A ST Co. Ltd.
  • Eli Lilly and Company
  • Bayer AG
  • Vivus Inc.
  • Teva Pharmaceutical Industries Ltd.
  • SK Chemicals
  • Meda Pharmaceuticals Inc.
  • Cristalia Produtos Quimicos Farmaceuticos Ltda. Apricus Biosciences Inc.
  • Futura Medical plc
  • 其他知名公司
Product Code: 20042-01-25

Erectile Dysfunction (ED) drugs are pharmaceutical agents used to treat erectile dysfunction, a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. ED drugs generally work by increasing blood flow to the penis, predominantly through the inhibition of specific enzymes that regulate blood vessel dilation. The most common class of ED drugs includes phosphodiesterase type 5 inhibitors (PDE5 inhibitors), but other drug classes are also used depending on the patient's health profile and the underlying cause of the dysfunction. The erectile dysfunction drugs market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.2%. This growth is driven by an increasing incidence of conditions such as diabetes, hypertension, and hormonal imbalances, which are often linked to the development of ED.

Aging Global Population

A primary driver for the erectile dysfunction (ED) drugs market is the globally aging population. As populations in developed and developing countries age, the incidence of chronic conditions such as diabetes, hypertension, and cardiovascular diseases-which are significant risk factors for ED-increases. Age is a strong demographic factor in ED prevalence; the condition affects about 5% of men in their 40s and 15-25% of men by the age of 65. This demographic trend is pushing demand for ED medications as older populations seek solutions to maintain a satisfactory quality of life. The increasing life expectancy and desire for an active lifestyle among older adults further fuel this demand, as more individuals seek to address health issues that affect their well-being and lifestyle quality.

Telemedicine and Online Pharmacies

The rise of telemedicine and online pharmacies presents a significant opportunity in the ED drugs market. With advancements in telehealth, patients can now have more private and convenient consultations, which is particularly important for conditions with social stigmas like ED. Online platforms provide discreet avenues for patients to seek treatment, which can increase the willingness to address and manage this condition. Furthermore, online pharmacies improve access to ED medications, especially in rural or underserved areas, broadening the market reach. These platforms often provide better pricing models and accessibility, making treatment options more affordable and prompt, thus potentially increasing market penetration and patient adherence to prescribed therapies.

Patent Expirations

A major restraint in the ED drugs market is the expiration of patents for key blockbuster drugs. As patents expire, generic versions enter the market, leading to a significant reduction in prices and revenue for the original drug manufacturers. For instance, the introduction of generic versions of sildenafil (Viagra) has dramatically decreased costs for patients but has also reduced the market share and revenue for Pfizer, the original manufacturer. While generics increase accessibility and affordability, they also thin profit margins for existing players in the branded pharmaceutical market, intensifying competition and putting pressure on the innovation of new therapies.

Regulatory and Safety Concerns

One of the significant challenges facing the ED drugs market is navigating the stringent regulatory environment and addressing safety concerns associated with these medications. ED drugs can have serious side effects and interactions with other medications, particularly nitrates used for heart disease, which can lead to unsafe drops in blood pressure. Ensuring patient safety while developing new formulations requires extensive clinical trials and robust safety studies, which are costly and time-consuming. Additionally, gaining regulatory approval for new drugs is a rigorous process, involving multiple phases of testing to prove efficacy and safety. These barriers can delay the introduction of new products to the market and involve substantial financial investment, presenting a challenge for pharmaceutical companies in the ED drugs sector.

Market Segmentation by Drug

In the erectile dysfunction (ED) drugs market, segmentation by drug includes Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and Others. Viagra (sildenafil citrate) historically holds the highest revenue within this segment due to its well-established brand, being the first approved oral treatment for ED in the late 1990s. Its widespread recognition and extensive clinical history have made it a preferred choice among patients and healthcare providers alike. However, Cialis (tadalafil) is expected to experience the highest CAGR moving forward. This anticipated growth is attributed to Cialis's longer half-life, which allows for greater spontaneity and has been a key differentiator from its competitors. Cialis's once-daily formulation option also enhances patient adherence and satisfaction, making it increasingly popular as a lifestyle drug beyond just the treatment of ED.

Market Segmentation by Distribution Channel

The market segmentation by distribution channel in the ED drugs market includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Retail pharmacies currently generate the highest revenue in this segment, benefiting from widespread accessibility and the convenience of obtaining medication. Many patients prefer purchasing their ED medications from retail pharmacies, where they can also seek advice and support from pharmacists. Conversely, Online Pharmacies are projected to witness the highest CAGR from 2025 to 2033. This growth is driven by the increasing consumer preference for privacy and convenience, coupled with competitive pricing models that online platforms often offer. The rise of telehealth services has also facilitated the growth of online pharmacies, as more patients receive prescriptions online and opt for home delivery services, enhancing the appeal and accessibility of purchasing ED medications through these channels.

Geographic Trends in the Erectile Dysfunction (ED) Drugs Market

The erectile dysfunction drugs market demonstrates distinct geographic trends, with North America leading in revenue generation in 2024. This is attributed to the region's high healthcare expenditure, widespread awareness of ED treatments, and the presence of key market players. Additionally, the advanced healthcare infrastructure and high prevalence of lifestyle-related health issues that contribute to ED, such as diabetes and hypertension, support robust market demand in North America. However, the Asia-Pacific region is expected to experience the highest CAGR from 2025 to 2033. Factors contributing to this growth include increasing healthcare awareness, rising disposable incomes, and the gradual destigmatization of discussing sexual health issues in these societies. Moreover, the expansion of healthcare systems and the increasing availability of ED medications in these markets are expected to drive significant growth.

Competitive Trends and Key Strategies

In 2024, the competitive landscape of the ED drugs market was shaped by strategic initiatives from leading players such as Pfizer, Inc., Eli Lilly and Company, Bayer AG, Vivus, Inc., Teva Pharmaceutical Industries Ltd., and others including Dong-A ST Co., Ltd., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Futura Medical plc. These companies focused extensively on research and development to introduce more effective and safer ED treatments. Pfizer and Eli Lilly, holding seminal products like Viagra and Cialis, respectively, dominated the market by maintaining strong brand loyalty and extensive global distribution networks. Innovations aimed at reducing side effects and enhancing patient convenience, such as fast-acting formulations and generics, were key areas of focus. From 2025 to 2033, these companies are expected to intensify their efforts towards diversification of their portfolios, including the exploration of ED treatments that address underlying conditions like hormonal imbalances or vascular health, beyond just the symptoms. Strategic partnerships, especially for global expansion and tapping into emerging markets, will likely be crucial. Moreover, the ongoing trend towards online pharmacies will prompt these companies to enhance their digital strategies to reach a broader customer base. Competitive pricing, patient education programs, and investments in telemedicine platforms are expected to be significant as companies adapt to changing consumer behaviors and increased market competition.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Erectile Dysfunction (ED) Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Erectile Dysfunction (ED) Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
    • Drug
  • Viagra
  • Cialis
  • Staxyn/Levitra
  • Stendra/Spedra
  • Others
    • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Erectile Dysfunction (ED) Drugs market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Erectile Dysfunction (ED) Drugs market?
  • Which is the largest regional market for Erectile Dysfunction (ED) Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Erectile Dysfunction (ED) Drugs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Erectile Dysfunction (ED) Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Erectile Dysfunction (ED) Drugs Market
  • 2.2. Global Erectile Dysfunction (ED) Drugs Market, By Drug, 2024 (US$ Million)
  • 2.3. Global Erectile Dysfunction (ED) Drugs Market, By Distribution Channel, 2024 (US$ Million)
  • 2.4. Global Erectile Dysfunction (ED) Drugs Market, By Geography, 2024 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2024

3. Erectile Dysfunction (ED) Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Erectile Dysfunction (ED) Drugs Market Vendors
  • 3.2. Strategies Adopted by Erectile Dysfunction (ED) Drugs Market Vendors
  • 3.3. Key Industry Strategies

4. Erectile Dysfunction (ED) Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Erectile Dysfunction (ED) Drugs Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Viagra
    • 5.3.2. Cialis
    • 5.3.3. Staxyn/Levitra
    • 5.3.4. Stendra/Spedra
    • 5.3.5. Others

6. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies

7. North America Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 7.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 7.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 7.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 7.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 7.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

8. UK and European Union Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 8.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 8.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.4.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.5.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.6.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

9. Asia Pacific Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 9.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 9.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.4.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.5.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.6.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

10. Latin America Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 10.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 10.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 10.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 10.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 10.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

11. Middle East and Africa Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 11.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 11.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 11.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 11.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 11.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

12. Company Profile

  • 12.1. Pfizer, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Dong-A ST Co., Ltd.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Eli Lilly and Company
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Bayer AG
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Vivus, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Teva Pharmaceutical Industries Ltd.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. SK Chemicals
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Meda Pharmaceuticals, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Cristalia Produtos Quimicos Farmaceuticos Ltda. Apricus Biosciences, Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Futura Medical plc
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Other prominent players
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 2 Global Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 3 North America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 4 North America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 5 U.S. Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 6 U.S. Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 7 Canada Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 8 Canada Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 9 Rest of North America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 10 Rest of North America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 11 UK and European Union Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 12 UK and European Union Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 13 UK Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 14 UK Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 15 Germany Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 16 Germany Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 17 Spain Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 18 Spain Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 19 Italy Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 20 Italy Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 21 France Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 22 France Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 23 Rest of Europe Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 24 Rest of Europe Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 25 Asia Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 26 Asia Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 27 China Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 28 China Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 29 Japan Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 30 Japan Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 31 India Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 32 India Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 33 Australia Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 34 Australia Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 35 South Korea Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 36 South Korea Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 37 Latin America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 38 Latin America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 39 Brazil Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 40 Brazil Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 41 Mexico Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 42 Mexico Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 43 Rest of Latin America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 44 Rest of Latin America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 45 Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 46 Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 47 GCC Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 48 GCC Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 49 Africa Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 50 Africa Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)

List of Figures

  • FIG. 1 Global Erectile Dysfunction (ED) Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Erectile Dysfunction (ED) Drugs Market: Quality Assurance
  • FIG. 5 Global Erectile Dysfunction (ED) Drugs Market, By Drug, 2024
  • FIG. 6 Global Erectile Dysfunction (ED) Drugs Market, By Distribution Channel, 2024
  • FIG. 7 Global Erectile Dysfunction (ED) Drugs Market, By Geography, 2024
  • FIG. 8 Market Geographical Opportunity Matrix - Global Erectile Dysfunction (ED) Drugs Market, 2024
  • FIG. 9Market Positioning of Key Erectile Dysfunction (ED) Drugs Market Players, 2024
  • FIG. 10 Global Erectile Dysfunction (ED) Drugs Market, By Drug, 2024 Vs 2033, %
  • FIG. 11 Global Erectile Dysfunction (ED) Drugs Market, By Distribution Channel, 2024 Vs 2033, %